The effect of COVID-19 vaccination during IVF stimulation on cycle outcomes- a retrospective cohort study.

COVID-19 IVF Pregnancy SARS-CoV-2 Vaccine

Journal

Journal of reproductive immunology
ISSN: 1872-7603
Titre abrégé: J Reprod Immunol
Pays: Ireland
ID NLM: 8001906

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 24 11 2023
revised: 15 02 2024
accepted: 09 04 2024
medline: 28 4 2024
pubmed: 28 4 2024
entrez: 27 4 2024
Statut: aheadofprint

Résumé

The effect of the mRNA-BNT162b2 vaccine administered prior to fertility treatments has been addressed in several studies, presenting reassuring results. Cycle outcomes of patients receiving the vaccine during the stimulation itself have not been previously described. This retrospective cohort study included patients who received mRNA-BNT162b2-vaccine during the stimulation of fresh IVF cycles, between January-September 2021, age matched to pre-stimulation vaccinated patients and to non-vaccinated patients. Demographics, cycle characteristics and cycle outcomes were compared between groups. A total of 132 in-treatment vaccinated patients (study group), 132 pre-treatment vaccinated and 132 non-vaccinated patients that underwent fresh IVF cycles were included. Mean time from vaccination to retrieval in the study group was 6.68 days (SD 3.74; range 0-12). Oocyte yield was similar between groups (9.35 versus10.22 and 10.05 respectively; p=0.491). A linear regression model demonstrated no effect of vaccination before or during the stimulation, on oocyte yield (p>0.999). Clinical pregnancy rates (30 % versus 30 % versus 28 %) and ongoing pregnancy rates (25 % for all groups) did not differ between groups. In a logistic regression model for clinical pregnancy rates, vaccine administration and timing of vaccination were not a significant factor. This is the first study reporting the outcome of the mRNA BNT162b2 vaccine administration during the IVF stimulation itself. The vaccine administration had no impact on fresh IVF treatment outcomes compared to pre-treatment vaccinated or non-vaccinated patients. This adds to the growing evidence of COVID-19 vaccine safety in relation to fertility treatments and enables more flexibility regarding timing of vaccine administration.

Identifiants

pubmed: 38677139
pii: S0165-0378(24)00055-X
doi: 10.1016/j.jri.2024.104246
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104246

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

Auteurs

Michal Youngster (M)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; IVF Unit, Herzliya Medical Centre, Herzliya, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel. Electronic address: michalyo@gmail.com.

Omer Maman (O)

Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Alon Kedem (A)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; IVF Unit, Herzliya Medical Centre, Herzliya, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Sarit Avraham (S)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; IVF Unit, Herzliya Medical Centre, Herzliya, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Moran Landau Rabbi (ML)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel.

Itai Gat (I)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Gil Yerushalmi (G)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Micha Baum (M)

IVF Unit, Herzliya Medical Centre, Herzliya, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel; IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Centre, Ramat-Gan, Israel.

Ariel Hourvitz (A)

IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Centre, Ramat-Gan, Israel.

Ettie Maman (E)

IVF Unit, Herzliya Medical Centre, Herzliya, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel; IVF Unit, Department of Obstetrics and Gynecology, Sheba Medical Centre, Ramat-Gan, Israel.

Classifications MeSH